Content area
Full Text
CPXtra generics scheme
by Adrienne de Mont
Numark has found that contractors stand to suffer serious losses from the new Drug Tariff prices that are unlikely to be recovered from advanced and enhanced services.
An analysis of data from 350 of its CPXtra members has shown an average loss around 25 per cent in cash profit following the price changes on April 1. The loss ranges from 10 per cent to 45 per cent, when comparing purchases at March prices with prices for April.
The loss depends on the prescription mix. Pharmacies with a high turnover of simvastatin, pravastatin and ramipril -...